Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners

Key Takeaways

  • Palisade Bio to present clinical data on LB1148 on prevention of post-surgical abdominal adhesions.
  • Ronald Hurst, MD, Principal Investigator of the study and Michael Dawson, MD, to participate in virtual presentation to review data and the need for new options to
  • The webinar will be hosted by Stonegate Capital Partners on March 16th at 8:30 am ET.

Dallas, Texas -- March 14, 2022 -- Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March 16th 2022 at 8:30 am ET and be available by replay. >> Click here to register or attend.

The data being discussed is also being presented at the American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting as an ePoster titled:

“Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148”

Palisade Bio’s Chief Medical Officer, Michael Dawson, M.D., will present the data and be joined by one of the investigators of the study, Ronald Hurst, M.D. The Angeles Clinic and Research Institute a Cedars-Sinai Affiliate, during a public webcast hosted by Stonegate Capital Partners the morning of March 16. Stonegate Managing Partner Shiv Kapoor will host the event.

Why Join

“There is a significant unmet need to prevent adhesions with almost seven million surgeries each year in the U.S. where patients are at risk for postoperative adhesions. Adhesions can be found in up to 90% of cases after intra-abdominal surgery. Some patients will suffer life-long complications, and it’s also estimated that the US medical system spends more than $2 billion dollars a year on treating patients with postoperative adhesions,” said Michael Dawson, M.D., Chief Medical Officer, Palisade Bio.

"With the medical system still looking for safe therapeutics to reduce abdominal adhesions, we are excited about the potential of LB1148 to prevent and mitigate costly and dangerous side effects of surgery. We look forward to sharing additional data on the incidence and severity of adhesions from the pooled analysis of patients treated with LB1148.”

About Stonegate Capital Partners

Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.


Key Takeaways

  • Palisade Bio to present clinical data on LB1148 on prevention of post-surgical abdominal adhesions.
  • Ronald Hurst, MD, Principal Investigator of the study and Michael Dawson, MD, to participate in virtual presentation to review data and the need for new options to
  • The webinar will be hosted by Stonegate Capital Partners on March 16th at 8:30 am ET.
Register for Webinar
Download

Media Gallery

Postoperative Complications are Driven by Proteolytic Activity
LB1148 Overview: Pipeline in a Product –Multiple Indications

Quotes

“
It’s estimated that the US medical system spends more than $2 billion dollars a year on treating patients with postoperative adhesions.
Michael Dawson, M.D. — Chief Medical Officer

Related Bios

Michael Dawson, M.D.
Chief Medical Officer
Michael Dawson, M.D. brings both clinical experience and a background in research and development to his role as chief medical officer at Palisade Bio (formerly Leading BioSciences). For more than two decades, he has served in leadership positions and on numerous hospital committees including the governing board at Centinela Hospital, providing him with key insights into the value of drug development and its application in the clinical setting. Dr. Dawson presently serves as chief of staff at Centinela Hospital Medical Center and has recently joined the administration of medical staffs to help shape the value of medicine and pharmaceuticals in the evolving U.S. healthcare system. He has participated in numerous clinical trials, notably leading gene therapy studies at the Children’s Hospital of Los Angeles which included some of the earliest adenovirus gene transfer studies. Dr. Dawson is a board-certified diagnostic radiologist with advanced qualification in vascular interventional radiology, having completed the vascular and interventional radiology and diagnostic radiology residency programs at the Keck School of Medicine at the University of Southern California. He earned his Doctor of Medicine (M.D.) degree from the University of Southern California. Working on the Human Genome project at the Howard Hughes Research facility at the University of California, San Diego, Dr. Dawson earned master’s degrees in biochemistry and cell biology with an honors thesis in molecular genetics from the University of California, San Diego.
View Full Bio>>
Ronald Hurst M.D.
Investigator of the Study
Dr. Ronald Hurst is a board-certified surgeon as part of the Division of Surgical Oncology at The Angeles Clinic and Research Institute. He completed his General Surgical training at Martin Luther King/Drew Medical Center, where he subsequently was selected as Executive Chief Resident, following which he completed Surgical Oncology training under Dr. Steven A. Rosenberg at the National Institutes of Health, National Cancer Institute in Bethesda Maryland. During his surgical oncology fellowship, the surgeon's research efforts were focused on tumor immunology analyzing TCRbV usage in response to tumor vaccines for melanoma using competitive PCR to quantitate the frequency of TCR subfamilies in PBMC.
View Full Bio>>
Shiv Kapoor
Managing Partner Healthcare Stonegate Capital Partners
Shiv has a BA in Biochemistry UC Berkeley, and an MBA from the University of Chicago Booth School of Business. He ran the Smith Barney Biotech fund at Citigroup and started Sellside Biotech practices at Montgomery & Co. and Morgan Joseph. In 2008 he was rated among the top three biotechnology analysts by Forbes in the US. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron’s Guide. In the past decade, Shiv had leading roles as an investor relations and strategy executive at Spectrum pharmaceuticals. He is the founder and CEO of BioRamon Pharmaceuticals, a biopharmaceutical company involved in the discovery and research of oncology medicine.
View Full Bio>>

Contacts

Erol Girgin
erol@stonegateinc.com
214.987.4121
Investors